Personally I see an intersect with many of the issues in pharmaceuticals and software patents. My particular interest is in so-called 'Low Dose Naltrexone' whic

Personally I see an intersect with many of the issues in pharmaceuticals and software patents. My particular interest is in so-called 'Low Dose Naltrexone' which I take for Crohn's Disease. The current system seems to neglect drugs which have multiple uses, particularly when said drug has gone out of patent, i.e. is cheap, as there is less of an incentive to do these hugely expensive trials in comparison to doing them for a newly patented, more profitable drug. This is not a 'big pharma' conspiracy, it's captialism + patents that is a big issue here and, as someone earlier said, it'd be a lot easier to address if it were just a conspiracy. As Goldacre shows, it's a flawed system that needs to be reformed to focus on patient health as much as, if not more than profits.